Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 3/20 | 0.49 |
| ▸ | MDM4 | O15151 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6507736 | 1.00 | KMT2A (0.52) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL31734716 | 1.00 | KMT2A (0.52) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL6629894 | 1.00 | KMT2A (0.52) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL31121697 | 1.00 | KMT2A (0.52) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL2307241 | 0.92 | KMT2A (0.53) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL119848 | 0.92 | KMT2A (0.53) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL29384904 | 0.92 | KMT2A (0.53) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL118281 | 0.92 | KMT2A (0.53) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL30851468 | 0.92 | KMT2A (0.53) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL29401270 | 0.92 | KMT2A (0.53) | KMT2AEPHX2CASP3MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360175-A1 | PEPTIDE DERIVATIVES AND RELATED USES AS OREXIN AGONISTS | OXFORD FINANCE LLC | 2024-10-31 | — | — | US | disclosed |
| CN-112279888-B | Polypeptide inhibitor of APC/Asef interaction and application thereof | 上海交通大学医学院 | 2022-09-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360175-A1 | PEPTIDE DERIVATIVES AND RELATED USES AS OREXIN AGONISTS | HCRTR2, HCRTR1, NPY1R | KMT2A 831/4885EPHX2 1129/4885CASP3 3146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.